BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, Niwa H, Kaibe N, Sasako M, Tomita T, Miwa H, Hirota S. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT. Eur J Radiol 2016;85:989-95. [PMID: 27130061 DOI: 10.1016/j.ejrad.2016.03.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Fujita I, Toyokawa T, Makino T, Matsueda K, Omote S, Horii J. Small early gastric cancer with synchronous bone metastasis: A case report. Mol Clin Oncol 2020;12:202-7. [PMID: 32064095 DOI: 10.3892/mco.2020.1985] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu Q, Li J, Xin B, Sun Y, Feng D, Fulham MJ, Wang X, Song S. 18F-FDG PET/CT Radiomics for Preoperative Prediction of Lymph Node Metastases and Nodal Staging in Gastric Cancer. Front Oncol 2021;11:723345. [PMID: 34589429 DOI: 10.3389/fonc.2021.723345] [Reference Citation Analysis]
3 Kitajima K, Hashimoto M, Katsuura T, Kondo N, Minami T, Kuribayashi K, Hasegawa S, Kijima T, Yamakado K. Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma - Comparison with contrast-enhanced CT. Oncotarget 2019;10:6816-28. [PMID: 31827724 DOI: 10.18632/oncotarget.27324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 van ’t Sant I, Engbersen MP, Bhairosing PA, Lambregts DMJ, Beets-tan RGH, van Driel WJ, Aalbers AGJ, Kok NFM, Lahaye MJ. Diagnostic performance of imaging for the detection of peritoneal metastases: a meta-analysis. Eur Radiol 2020;30:3101-12. [DOI: 10.1007/s00330-019-06524-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
5 Bosch KD, Chicklore S, Cook GJ, Davies AR, Kelly M, Gossage JA, Baker CR. Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. Eur J Nucl Med Mol Imaging 2020;47:759-67. [PMID: 31377821 DOI: 10.1007/s00259-019-04429-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Wu C, Lin X, Li Z, Chen Z, Xie W, Zhang X, Wang X. A Diagnostic Nomogram Based on 18F-FDG PET/CT for Bone Metastasis of Gastric Cancer. Front Cell Dev Biol 2021;9:783466. [PMID: 34970546 DOI: 10.3389/fcell.2021.783466] [Reference Citation Analysis]
7 Voron T, Romain B, Bergeat D, Véziant J, Gagnière J, Le Roy B, Pasquer A, Eveno C, Gaujoux S, Pezet D, Gronnier C; sous l’égide de l’Association française de chirurgie (AFC)., Collaborateurs (relecteurs). Surgical management of gastric adenocarcinoma. Official expert recommendations delivered under the aegis of the French Association of Surgery (AFC). J Visc Surg 2020;157:117-26. [PMID: 32151595 DOI: 10.1016/j.jviscsurg.2020.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hashimoto Y, Ajiki T, Yanagimoto H, Tsugawa D, Shinozaki K, Toyama H, Kido M, Fukumoto T. Risk factors for occult metastasis detected by inflammation-based prognostic scores and tumor markers in biliary tract cancer. World J Clin Cases 2021; 9(32): 9770-9782 [PMID: 34877316 DOI: 10.12998/wjcc.v9.i32.9770] [Reference Citation Analysis]
9 Li S, Zhao Z, Yang H, Wang D, Sun W, Li S, Zhang Z, Fu W. Construction and Validation of a Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer. Cancer Control 2021;28:10732748211027160. [PMID: 34155937 DOI: 10.1177/10732748211027160] [Reference Citation Analysis]
10 Zhang Z, Zheng B, Chen W, Xiong H, Jiang C. Accuracy of 18F-FDG PET/CT and CECT for primary staging and diagnosis of recurrent gastric cancer: A meta-analysis. Exp Ther Med 2021;21:164. [PMID: 33456531 DOI: 10.3892/etm.2020.9595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Yuan Y, Chen L, Ren S, Wang Z, Chen Y, Jin A, Li S, Fang X, Wang T, Bian Y, Yang Q, Bai C, Hao Q, Lu J. Diagnostic performance in T staging for patients with esophagogastric junction cancer using high-resolution MRI: a comparison with conventional MRI at 3 tesla. Cancer Imaging 2019;19:83. [PMID: 31801587 DOI: 10.1186/s40644-019-0269-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Kim M, Jeong WK, Lim S, Sohn TS, Bae JM, Sohn IS. Gastric cancer: development and validation of a CT-based model to predict peritoneal metastasis. Acta Radiol 2020;61:732-42. [PMID: 31653185 DOI: 10.1177/0284185119882662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Xue XQ, Wang B, Yu WJ, Zhang FF, Niu R, Shao XL, Shi YM, Yang YS, Wang JF, Li XF, Wang YT. Relationship between total lesion glycolysis of primary lesions based on 18F-FDG PET/CT and lymph node metastasis in gastric adenocarcinoma: a cross-sectional preliminary study. Nucl Med Commun 2022;43:114-21. [PMID: 34406147 DOI: 10.1097/MNM.0000000000001475] [Reference Citation Analysis]
14 Pelc Z, Skórzewska M, Rawicz-Pruszyński K, Polkowski WP. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel) 2021;13:2509. [PMID: 34065596 DOI: 10.3390/cancers13102509] [Reference Citation Analysis]
15 Borggreve AS, Goense L, Brenkman HJF, Mook S, Meijer GJ, Wessels FJ, Verheij M, Jansen EPM, van Hillegersberg R, van Rossum PSN, Ruurda JP. Imaging strategies in the management of gastric cancer: current role and future potential of MRI. Br J Radiol 2019;92:20181044. [PMID: 30789792 DOI: 10.1259/bjr.20181044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
16 Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K, Tsurusaki M, Doi H, Ueno Y, Sofue K, Tamaki Y, Yamakado K. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. Nagoya J Med Sci 2017;79:527-43. [PMID: 29238109 DOI: 10.18999/nagjms.79.4.527] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
17 Chen X, Chen S, Wang X, Nie R, Chen D, Xiang J, Lin Y, Chen Y, Peng J. Analysis and external validation of a nomogram to predict peritoneal dissemination in gastric cancer. Chin J Cancer Res 2020;32:197-207. [PMID: 32410797 DOI: 10.21147/j.issn.1000-9604.2020.02.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Xue B, Jiang J, Chen L, Wu S, Zheng X, Zheng X, Tang K. Development and Validation of a Radiomics Model Based on 18F-FDG PET of Primary Gastric Cancer for Predicting Peritoneal Metastasis. Front Oncol 2021;11:740111. [PMID: 34765549 DOI: 10.3389/fonc.2021.740111] [Reference Citation Analysis]
19 Liang C, Chen H, Yang Z, Han C, Ren C. Risk factors and prognosis of bone metastases in newly diagnosed gastric cancer. Future Oncol 2020;16:733-48. [PMID: 32285687 DOI: 10.2217/fon-2019-0728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Marcus C, Subramaniam RM. PET/Computed Tomography and Precision Medicine: Gastric Cancer. PET Clin 2017;12:437-47. [PMID: 28867114 DOI: 10.1016/j.cpet.2017.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
22 Zhang Y, Lin Y, Duan J, Xu K, Mao M, Wang X. A Population-Based Analysis of Distant Metastasis in Stage IV Gastric Cancer. Med Sci Monit 2020;26:e923867. [PMID: 32409630 DOI: 10.12659/MSM.923867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yoon JK, Byun C, Jo KS, Hur H, Lee KM, Lim SK, Lee D, Lee SJ, An YS, Han SU. Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using 18F-FDG PET. Medicine (Baltimore) 2019;98:e16690. [PMID: 31374056 DOI: 10.1097/MD.0000000000016690] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Chen S, Nie RC, OuYang LY, Li YF, Xiang J, Zhou ZW, Chen Y, Peng JS. Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer. Oncotarget 2017;8:11380-8. [PMID: 28077786 DOI: 10.18632/oncotarget.14535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
25 Tada K, Etoh T, Shitomi Y, Ueda Y, Tojigamori M, Shiroshita H, Shiraishi N, Inomata M. A case of advanced gastric cancer achieved a pathological complete response by chemotherapy. Surg Case Rep 2017;3:68. [PMID: 28500392 DOI: 10.1186/s40792-017-0344-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Berlth F, Chon SH, Chevallay M, Jung MK, Mönig SP. Preoperative staging of nodal status in gastric cancer. Transl Gastroenterol Hepatol 2017;2:8. [PMID: 28217758 DOI: 10.21037/tgh.2017.01.08] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Tasdemir B, Güzel Y, Komek H, Can C. Evaluation of dual time-point fluorodeoxyglucose PET/computed tomography imaging in gastric cancer. Nucl Med Commun 2020;41:1322-7. [PMID: 32956249 DOI: 10.1097/MNM.0000000000001290] [Reference Citation Analysis]
28 Arslan E, Aksoy T, Gündoğan C, Şen Ç, Yılmaz Tatar S, Dursun N, Çermik TF. Metabolic Characteristics and Diagnostic Contribution of 18F-FDG PET/CT in Gastric Carcinomas. Mol Imaging Radionucl Ther 2020;29:25-32. [PMID: 32079385 DOI: 10.4274/mirt.galenos.2020.75537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Perlaza P, Ortín J, Pagès M, Buxó E, Fernández-Esparrach G, Colletti PM, Rubello D, Mayoral M, Sánchez N, Ruiz C, Ginés A, Fuster D. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? Clin Nucl Med 2018;43:402-10. [PMID: 29485442 DOI: 10.1097/RLU.0000000000002028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
30 Seko-Nitta A, Nagatani Y, Murakami Y, Watanabe Y, Nitta N, Murata K, Takemura S, Murata S. 18F-fluorodeoxyglucose uptake in advanced gastric cancer correlates with histopathological subtypes and volume of tumor stroma. Eur J Radiol 2021;145:110048. [PMID: 34814038 DOI: 10.1016/j.ejrad.2021.110048] [Reference Citation Analysis]